Hemofiltration for Respiratory Failure After Bone Marrow Transplantation

Respiratory Insufficiency Clinical Trial

Official title:

Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00120575
• Other study ID #: BMT CVVH
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: July 11, 2005
• Last updated: December 1, 2006
• Start date: January 2005
• Est. completion date: September 2008

Study information

• Verified date: December 2006
• Source: Stanford University
• Contact: Joseph V DiCarlo, MD
• Phone: (650) 497-8850
• Email: jdicarlo[@]stanford.edu
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

For children undergoing bone marrow transplantation, respiratory failure is a devastating complication, with mortality expectations well above 60%. The researchers have devised a novel strategy that may greatly improve survival. Hemofiltration, a continuous form of dialysis, was designed as a therapy for critically ill patients with kidney failure. A semi-permeable membrane removes plasma water and solutes (up to about 35,000 Daltons molecular weight). The researchers have treated immuno-compromised children with respiratory failure with hemofiltration. Many inflammatory molecules are of a size well below the limit of the filter. Hemofiltration might remove a critical amount of this inflammatory material, attenuating the unregulated inflammatory response that is central to the development of respiratory failure and progression to multiple organ failure and death. The researchers are conducting a multi-center trial of early continuous hemofiltration for respiratory failure in children following bone marrow transplantation. The researchers will analyze blood and ultrafiltrate using sensitive proteomic methods to detect several inflammatory biochemicals known to be active in this disease, looking for evidence that early active hemofiltration alters the inflammatory response. The researchers will test whether `early` hemofiltration produces greater survival from respiratory failure in this vulnerable population.

Description:

For children undergoing bone marrow transplantation, respiratory failure carries mortality expectations well above 60%. The researchers have published preliminary evidence that continuous hemofiltration may greatly improve survival, if filtration is begun when the child first fulfills clinical criteria for ARDS. This is a departure from standard practice, as hemofiltration is usually begun later in the course (if at all) when multiple organ failure is entrenched. Hemofiltration, a `renal replacement therapy` for critically ill patients, is a slow, continuous process in which a semi-permeable membrane removes plasma water and solutes (up to about 35 kiloDaltons). Many cytokine and chemokine molecules are smaller than the molecular weight limit of the filter; hemofiltration might remove a critical amount, attenuating the unregulated inflammatory response responsible for respiratory failure and progression to multiple organ failure and death. The researchers will conduct a multi-center randomized trial assessing the effect of hemofiltration on survival from respiratory after bone marrow (or more precisely, hematopoietic stem cell) transplantation. The researchers will perform sensitive proteomic assays of serum and ultrafiltrate, to detect the presence of cytokines and chemokines known to be active in idiopathic pneumonia syndrome. Resulting profiles will constitute a uniquely complex description of ultrafiltrate and may provide evidence for modulation of immune function by hemofiltration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Month to 21 Years

Eligibility

Inclusion Criteria:

• hematopoietic stem cell recipient

• respiratory failure fulfilling ARDS criteria

• mechanical ventilation (invasive / non-invasive)

Exclusion Criteria:

• extracorporeal membrane oxygenation (ECMO)

• predominance of congestive heart failure

• code status: a patient must be willing to accept invasive mechanical ventilation if clinically indicated

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bone Marrow Transplantation
• Pulmonary Valve Insufficiency
• Respiratory Insufficiency

Intervention

Procedure:
• hemofiltration

Locations

Country	Name	City	State
Canada	Children's Hospital of British Columbia	Vancouver	British Columbia
Germany	University of Ulm	Ulm
United Kingdom	Great Ormond Street Hospital	London
United States	Children's Healthcare of Atlanta @ Egleston	Atlanta	Georgia
United States	Duke University	Durham	North Carolina
United States	Children's Hospital and Research Center	Oakland	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Countries where clinical trial is conducted

United States,  Canada,  Germany,  United Kingdom, 

References & Publications (2)

Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 Aug;28(8):777-86. Review. — View Citation

DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol. 2003 Oct;25(10):801-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival
Secondary	PELOD organ failure score
Secondary	number of ventilator-free days
Secondary	duration of hospitalization
Secondary	functional outcome score